Subscribe
Technology

Quest Diagnostics, Myriad Genetics settle gene-patent litigation

By Jessica Karmasek
Published
Add Washington Examiner on Google

MADISON, N.J. (Legal Newsline) – Quest Diagnostics announced Monday that it and Myriad Genetics Inc. have reached an agreement that will end litigation over patents on two genes associated with hereditary breast and ovarian cancer.

 

Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.

Tag:

Law Science